See more : Galectin Therapeutics Inc. (GALT) Income Statement Analysis – Financial Results
Complete financial analysis of Connect Biopharma Holdings Limited (CNTB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Connect Biopharma Holdings Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Qatar Insurance Company Q.S.P.C. (QATI.QA) Income Statement Analysis – Financial Results
- Sino-Ocean Group Holding Limited (SIOLY) Income Statement Analysis – Financial Results
- Life360, Inc. (360.AX) Income Statement Analysis – Financial Results
- Canadian Pacific Railway Limited (CP.TO) Income Statement Analysis – Financial Results
- XP Chemistries AB (publ) (XPC.ST) Income Statement Analysis – Financial Results
Connect Biopharma Holdings Limited (CNTB)
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 988.00K | 1.03M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -988.00K | -1.03M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 51.91M | 95.26M | 81.34M | 23.12M | 15.44M |
| General & Administrative | 14.52K | 20.37M | 19.23M | 7.31M | 1.41M |
| Selling & Marketing | 13.51M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.53M | 20.37M | 19.23M | 7.31M | 1.41M |
| Other Expenses | -4.35M | -940.31K | -2.98M | -1.07M | -411.44K |
| Operating Expenses | 62.07M | 114.69M | 97.59M | 29.36M | 16.44M |
| Cost & Expenses | 62.07M | 114.69M | 97.59M | 29.36M | 16.44M |
| Interest Income | 5.20K | 1.56M | 97.67K | 109.84K | 154.65K |
| Interest Expense | 0.00 | 21.03K | 6.91K | 6.43K | 7.69K |
| Depreciation & Amortization | 988.00K | 1.01M | 640.98K | 221.05K | 114.61K |
| EBITDA | -58.37M | -111.31M | -204.93M | -118.21M | -24.78M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -62.07M | -117.66M | -99.15M | -30.30M | -15.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.69M | -403.66K | -103.21M | -89.07M | -8.41M |
| Income Before Tax | -59.38M | -116.12M | -204.94M | -119.37M | -24.46M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 120.00K | 297.52K | 266.47K | 934.46K | -442.49K |
| Net Income | -59.50M | -116.42M | -205.21M | -120.30M | -24.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.08 | -14.50 | -25.00 | -14.45 | -3.02 |
| EPS Diluted | -1.08 | -14.50 | -25.00 | -14.45 | -3.02 |
| Weighted Avg Shares Out | 55.07M | 55.04M | 52.27M | 53.94M | 55.82M |
| Weighted Avg Shares Out (Dil) | 55.07M | 55.04M | 52.27M | 53.94M | 55.82M |
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Connect Biopharma to Participate in Upcoming September Investor Conferences
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
CNTB Stock Surges Over 20%: Explanation
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
Connect Biopharma stock up more than 40% after trial data
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California
Source: https://incomestatements.info
Category: Stock Reports